Beyond Dialysis: Pig Kidney Xenotransplants, Implantable and Wearable Artificial Kidneys, Stem Cells and Organoids — Where Each Stands (October 2026)

The most important thing first: as of October 2026, none of the therapies below is approved for routine use or can replace dialysis or a human kidney transplant. They sit in clinical trials, animal studies or the laboratory. This article is meant to show where the world is heading — not to suggest delaying current treatment while waiting. Any paid program claiming to "cure" kidney failure with stem cells has no reliable evidence today.

Status at a Glance

1. Gene-Edited Pig Kidney Xenotransplantation

What it is

Using CRISPR and related tools to edit the pig genome — knocking out sugar antigens that trigger hyperacute rejection, adding human complement- and coagulation-regulating genes, and removing porcine endogenous retroviruses — so a pig kidney is less likely to be attacked by the human immune system, then transplanting it into a patient with end-stage kidney disease.

Where it stands

• 2021–2024: short-term studies in brain-dead donors (NYU Langone, University of Alabama).
• March 2024: Massachusetts General Hospital performed the world's first gene-edited pig kidney transplant into a living person (eGenesis); he died about two months later of cardiac causes with a functioning kidney.
• November 2024: Towana Looney received United Therapeutics' 10-gene-edited UKidney at NYU Langone; it was removed after 130 days when an unrelated infection led to rejection, and she resumed dialysis.
• January 2025: Tim Andrews received an eGenesis pig kidney at MGH and lived with it for 271 days — the longest on record. It was removed in October 2025 for declining function and he returned to dialysis. He was dialysis-free throughout.
• February 2025: the FDA cleared formal clinical trials for both United Therapeutics (EXPAND, NCT06878560) and eGenesis.
• November 2025: the first EXPAND surgery was performed at NYU Langone. The trial is a combined phase 1/2/3 ("phaseless") design: a first cohort of six at two centers, 24-week follow-up, then an independent committee decides on expansion; success would support a BLA for approval.

Who might qualify

EXPAND criteria: age 55–70, end-stage kidney disease, at least six months on hemodialysis, compatible crossmatch, no severe cardiovascular, pulmonary or neurological disease or uncontrolled diabetes, and unlikely to receive a human kidney in time.

What patients should know

• Every case so far has needed heavier immunosuppression than a human transplant; infection and rejection remain the main problems.
• The longest survival is under a year — not yet a lifetime solution, but it has proven that months of dialysis-free life on a pig kidney is possible in humans.
• Trials run only at a few US centers; there are no human trials in Taiwan or Japan.

Sources

• NYU Langone Health. First Gene-Edited Pig Kidney Transplant Clinical Trial Begins. Nov 2025. https://nyulangone.org/news/first-gene-edited-pig-kidney-transplant-clinical-trial-begins-nyu-langone-health
• ClinicalTrials.gov NCT06878560 (EXPAND)
• American Kidney Fund. FDA greenlights first clinical trials for genetically modified pig kidney transplants. Feb 2025.
• National Kidney Foundation. Pig Kidney Transplants in Humans: Xenotransplantation Explained.
• Nashan B, et al. The First Clinical Renal Xenotransplantation Study (EXPAND). 2025. PMC12728669
• CNN. Pig kidney removed from New Hampshire man after record 271 days. 27 Oct 2025.

2. The Implantable Bioartificial Kidney (The Kidney Project)

What it is

Led by Shuvo Roy, PhD (UCSF) and William Fissell, MD (Vanderbilt). A coffee-cup-sized device with two core parts:

1. HemoCartridge: silicon nanopore membranes driven by blood pressure — no pump, no power — filtering toxins and water.
2. BioCartridge: a bioreactor housing living human kidney tubule cells for reabsorption, electrolyte balance and hormone secretion; the pores are too small for immune cells, so in theory no immunosuppressants are needed.

Where it stands

• 2021: won a KidneyX Artificial Kidney Prize (phase 1).
• 2023: Nature Communications paper — a bioreactor with living kidney cells implanted in pigs for 7 days, cells survived and functioned, without immunosuppression.
• Early 2026: the team reported extending implantation time and continuing toward long-term implants.
• No human clinical trials have begun. The official FAQ states: "The implantable bioartificial kidney is under development, and we have not begun clinical trials."

What patients should know

This is the closest concept to the ideal of "no dialysis, no immunosuppression, no donor wait", but human trials are still some distance away, let alone market approval. Do not trust any message offering to "book" an artificial kidney implant.

Sources

• UCSF. The Kidney Project. https://pharm.ucsf.edu/kidney/the-kidney-project
• UCSF. Frequently Asked Questions by Patients. https://pharm.ucsf.edu/kidney/device/faq
• Kim EJ, et al. Feasibility of an implantable bioreactor for renal cell therapy using silicon nanopore membranes. Nat Commun. 2023.

3. Portable and Wearable Artificial Kidneys

NeoKidney (Nextkidney — Netherlands / Switzerland / Singapore)

• A suitcase-sized (~10 kg) home hemodialysis machine with closed-loop dialysate regeneration: about 4.5 L per session instead of ~30 L, and no home plumbing or electrical modifications.
• Designed for 4–7 sessions of 2 hours per week, giving gentler, more frequent dialysis with smaller swings.
• From January 2026, about 50 patients at UMC Utrecht began a home-use clinical study; interim results go to an independent notified body, targeting CE certification in 2026–2027, with results expected in 2027.
• Note: it is still dialysis, not freedom from dialysis — but far more flexible and travel-friendly.

VIVANCE (formerly AWAK, Singapore)

• A waist-pack wearable peritoneal dialysis device that regenerates PD fluid.
• Early safety study published 2022 (Peritoneal Dialysis International); still in development, not on the market.

Wearable Artificial Kidney (WAK, Dr Victor Gura, USA)

• A wearable hemodialysis prototype; an FDA-approved small human trial (7 patients, 24 h) was completed in 2016, with ongoing refinement and no launch date.

Sources

• UMC Utrecht / Utrecht University. Patients test portable artificial kidney at home for the first time. 15 Jan 2026. https://www.uu.nl/en/news/patients-test-portable-artificial-kidney-at-home-for-the-first-time
• Nextkidney. https://nextkidney.com/
• Kidney Care UK. Kidney Technologies on the Horizon. Jun 2025.
• Wieringa FP, et al. Transportable, portable, wearable and (partially) implantable haemodialysis systems. 2024. PMC11411285
• National Kidney Foundation. A Dream Starting to Come True: Wearable Kidneys.

4. Stem Cells and Kidney Organoids

What it is

Differentiating human pluripotent stem cells (iPS or embryonic) in the dish into "mini-kidneys" containing glomerular and tubular structures. Two long-term paths:

1. Regeneration: implanting organoids or progenitor cells into a damaged kidney to restore function.
2. Organ manufacture: using an "embryonic kidney niche" in an animal (e.g. pig) to grow a whole kidney from human cells for transplant — the direction pursued by Prof. Takashi Yokoo's team at Jikei University, Japan.

Where it stands

• Organoids are used mainly for disease modelling and drug testing; they are small, lack full vasculature and a urinary outlet, and have limited function.
• 2024–2025: the Yokoo team published human–pig chimeric kidney organoids and fetal-to-fetal kidney transplantation in animals (Communications Biology, Nature Communications). Japan permits basic research growing human organs in animal embryos.
• Sheba Medical Center (Israel), MCRI (Australia) and Leiden (Netherlands) are advancing vascularized organoids.
• No human trials have begun. Most experts estimate 10+ years to clinical use.

Mesenchymal stem cell (MSC) infusion

• Different from "growing a kidney": these studies inject bone-marrow- or fat-derived MSCs hoping anti-inflammatory and repair signals slow CKD progression.
• Several small phase 1/2 trials show short-term safety and some slowing of eGFR decline, but no trial has shown a cure for kidney failure or freed dialysis patients from dialysis.
• Neither the US FDA nor Taiwan's MOHW has approved any stem-cell indication for kidney disease. Commercial stem-cell programs (including medical tourism) should be regarded as unproven and risky experimental services.

Sources

• Fujimori K, et al. Generation of human-pig chimeric renal organoids. Commun Biol. 2024.
• Morimoto K, et al. Fetal-to-fetal kidney transplantation in utero. Commun Biol. 2025.
• Zhao Z, et al. Advances and future perspectives of kidney organoid. Front Med. 2026.
• Wong CY. Current advances of stem cell-based therapy for kidney diseases. 2021. PMC8316868
• Murdoch Children's Research Institute. Kidney Regeneration.

5. Practical Advice for Patients

1. The best option available today is still: stable dialysis + listing for a human transplant + looking after your heart and muscles. Nearly every trial requires "stable health" to enrol — taking care of yourself is what makes you a future candidate.
2. Want to join a trial? Ask your transplant or kidney doctor. Legitimate trials are registered on ClinicalTrials.gov, Japan's jRCT or national registries, and never charge participants.
3. Stay highly sceptical of "stem cells cure kidney disease." Anything that charges a fee, has no trial registration number, or promises "no more dialysis" is not supported by current science.
4. Keep hope, and keep patience. Xenotransplantation went from brain-dead studies in 2021 to formal trials in 2025 in four years; a portable artificial kidney may reach the European market in 2027. The direction is right — it just needs time.

This article will be updated as trial results are published.

This article summarizes publicly available medical information for educational purposes and is not medical advice. For any questions about your health, illness or physical care, please seek help through professional medical channels and consult your physician.